BLOCKERS OF NMDA RECEPTOR FOR THE TREATMENT OF SICKLE CELL ANEMIA

Abstract: Sickle cell anemia is a genetic disease characterized by red blood cells that assume an abnormal, rigid, sickle shape. Acute complications of Sickle cell anemia are treated symptomatically with analgesics and transfusions, and a prophylactic treatment of sickle cell crisis is long term application of hydroxyurea. According to the present invention, an N-methyl D-aspartate receptor (NMDAR) blocker is used for the treatment of sickle cell anemia and for manufacture of a medicament for the treatment of sickle cell anemia. Moreover, a method for screening for a compound effective in the treatment of sickle cell anemia comprises contacting a candidate compound with the NMDAR and selecting said candidate compound as effective if it is found to selectively reduce activity of the NMDAR.
Published: international search report (Art. 21(3))
Blockers of NMDA receptor for the treatment of sickle cell anemia

Field of the invention
This invention relates to the treatment of sickle cell anemia, using blockers of NMDA.

Background of the invention
The N-methyl D-aspartate receptor (NMDAR) is an ionotropic receptor for glutamate. Blockers of NMDAR have been used as anesthesia and for treatment of traumatic brain injury, stroke, and neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's.

This invention focuses on the treatment of sickle cell anemia, a genetic disease characterized by red blood cells that assume an abnormal, rigid, sickle shape. Acute complications of Sickle cell anemia are treated symptomatically with analgesics and transfusions. A prophylactic treatment of sickle cell crisis is long term application of hydroxyurea. Further treatment options are very desirable.

Summary of the invention
The present invention relates to a method of treating sickle cell anemia, using blockers of the NMDAR. Furthermore the invention relates to blockers of the NMDAR for use in the treatment of sickle cell anemia.

The invention further relates to a method of screening for a compound effective in the treatment of sickle cell anemia, comprising contacting a candidate compound with the NMDAR and choosing candidate compounds which selectively reduce activity of the NMDAR. The invention further relates to compounds selected by these methods of screening.

Brief description of the drawings
Fig. 1: Samples 1-3 are from three patients with sickle cell anemia. Shown is the specific staining against the NR1 subunit of the NMDA receptor (NRX) and the loading control (LC) of the light (L), middle (M) and high density (H) sub-populations of erythrocytes.

Fig. 2: Potassium and calcium fluxes through the NMDA receptor in erythrocytes of healthy donors (C) and patients with sickle cell anemia (H). A: Unidirectional K+ influx measured in chloride-free Na-methane sulfate medium in the presence of 100 µM ouabain, the inhibitor of Na,K-ATPase. Conditions corresponding to the numbers at the X axis: (1) control; (2) 50 µM memantine chloride (Sigma-Aldhedge); (3) 100 µM NMDA; (4) NMDA + memantine chloride; (5) 2 µM prostaglandine E2 (PGE2); (6) PGE2 + memantine chloride. * denotes p<0.05 compared to the corresponding values in healthy donor's erythrocytes, # stands for p<0.05 compared to the corresponding non-treated control. Data are means ± SEM for 6-7 individuals. B: Unidirectional Ca2+ influx in erythrocytes of a single HbSS patient measured on 3 different occasions and in three healthy donors. Conditions indicated in numbers at the X axis are: (1) non-treated control; (2) 100 µM NMDA; (3) 100 µM NMDA and 50 µM MK-801. * denotes p<0.05 compared to the corresponding health donors' samples.

Fig. 3: The examples of morphological changes in erythrocytes caused by agonists and antagonists of the NMDA receptor depending on the receptor availability and HbSS presence. Sample 1 is a sample from a sickle cell patient, sample 2 is from a person with high levels of NMDA receptors and reticulocytes is and sample 3 is from a person with low levels of receptors. Treatment 1 denotes administration of 50 µM memantine (sample 2) or MK-801 (sample 3), treatment 2 stands for 1 mM NMDA addition, treatment 2 shows morphological changes in the
cells pre-treated with memantine/MK-801 and then exposed to 1 mM NMDA.

**Detailed description of the invention**

The present invention relates to a method of treating sickle cell anemia, comprising administering blockers of the NMDAR, and the use of such blockers in said treatment and in the manufacture of medicaments for treating sickle cell anemia.

The action of the NMDAR can be blocked by administration of antibodies or antibody fragments directed against the NMDAR, of molecules that affect the protein or mRNA expression of the NMDAR (siRNA; miRNA), as well as of small molecules that interfere with the binding of ligands to the NMDAR (e.g. blocking the binding site of the neurotransmitter glutamate or the glycine site; or inhibiting NMDAR by binding to allosteric sites or blocking the ion channel by binding to a site within it). A further way to prevent binding to the NMDAR is to use soluble NMDAR or fragments thereof.

Examples of NMDAR blockers according to the invention are disclosed in the following. However, the invention is not restricted to the blockers disclosed therein, but extends to all blockers of NMDAR.

Preferred blockers of NMDAR according to the invention are:

- Soluble NMDAR or fragments thereof

- Antibodies that bind to NMDAR, antigen binding fragments of an antibody (e.g. Fab fragments) or antibody-like molecules (e.g. repeat proteins) which by binding to NMDAR block its biological activity. Antibodies against NMDAR are known in the art and include the well characterized antibody NMDA NR 1 Pan Antibody, mouse monoclonal, Novus biologicals, NB 300-1 18.
Virus-like particles loaded with NMDAR or fragments thereof and therefore inducing an antibody response directed against NMDAR with the effect to block its biological activity.

Antisense molecules for downregulation of NMDAR. These antisense molecules are approximately 12-50 nucleotides in length and encode a given sequence found in the exons or introns of NMDAR. Moreover, antisense molecules containing a sequence of the NMDAR promoters and binding within the promoter region may be used. Finally, antisense molecules binding in the 3' UTR-non translated regions of NMDAR are contemplated.

Small molecules that block the biological activity of NMDAR. Small molecules contemplated are synthetic compounds up to a molecular weight of approximately 1000 which have suitable physiological activity and pharmacological properties making them useful for the application as medicaments. Such small synthetic molecules are, for example, found by the screening method of the present invention described below. Alternatively, such small molecules are designed by molecular modelling taking into account possible binding sites of NMDAR.

Proteins and protein analogs which bind NMDAR and thereby inhibit its biological activity, for example, synthetic proteins or protein analogs which mimic the variable region of binding and/or neutralizing antibodies, or antibodies that mimic a binding pocket of the NMDAR. Likewise small molecules could be applied, which mimic the variable region of binding and/or neutralizing antibodies, or that mimic a binding pocket of the NMDAR.

Particularly preferred blockers are:
- Amantadine (Novartis, Actavis, Pharmascience)
- Dextromethorphan, Dextrorphan (e.g. Johnson & Johnson)
- Ibogaine
- Ketamine (e.g. Javeline Pharmaceuticals)
- Nitrous oxide
- Phencyclidine
- Riluzole (Sanofi-Aventis)
- Tiletamine
- Memantine (Allergan, Daiichi Sankyo, Forest Laboratories, Lundbeck)
- Dizocilpine (MK-801)
- Aptiganel (Cerestat, CNS-1 102)
- Remacimide
- HU-21 1, an enantiomer of the potent cannabinoid HU-21 0
- 7-Chlorokynurenate
- DCKA (5,7-dichlorokynurenic acid)
- Kynurenic acid, a naturally occurring antagonist
- 1-Aminocyclopropanecarboxylic acid (ACPC)
- Lacosamide
- AP7 (2-amino-7-phosphonoheptanoic acid)
- APV (R-2-amino-5-phosphonopentanoate)
- CPPene (3-[[(R)-2-carboxypiperazin-4-yl]-prop-2-enyl]-1-phosphonic acid)
- flupirtine (Adeona Pharmaceuticals, Inc.)
- orphenadrine (Actavis, Akorn)
- Neu2000KL (Amkor Pharma, Neurotech)
- AZD6765 (Astra-Zeneca)
- AM-1 0 1 (Auris Medical)
- Indantadol (Chiesi Farmaceutici, Vernalis)
- C-1 0003 (Concert Pharmaceuticals)
- EVT1 01, EVT1 02, EVT1 03 (Evotec)
- Radiprodil (Forrest Laboratories)
- Gacyclidine (1-[[1 R,2S)-2-methyl-1-thiophen-2-yl-cyclohexyl]pipehdine; Neureva)
- CNS 5 1 6 1 (2-(2-chloro-5-methylsulfanyl-phenyl)-1-methyl-1-(3-methylsulfanyl-phenyl)guanidine; Paion)
- Dexanabinol and other dextro cannabino id compounds (Pharmos)
- CR3394 (Rottapharm)
- Felbamate ((S-carbamoyloxy-phenyl-propyl) carbamate; Schering-Plough)
- TXT0300 (Traxion Therapeutics)
- AV101 (Z-chloro-oxo-I H-quinoline-carboxylic acid; VistaGen Therapeutics)
- YT1006 (Yaupon Therapeutics)

Most preferred blockers are:
- Memantine (Allergan, Daiichi Sankyo, Forest Laboratories, Lundbeck)
- Dizocilpine (MK-801)

One aspect of the invention relates to a method of preventing and treating sickle cell anemia, comprising administering blockers the NMDAR as defined hereinbefore in a quantity effective against sickle cell anemia to a mammal in need thereof, for example to a human requiring such treatment. For the administration, the blocker is preferably in the form of a pharmaceutical preparation comprising the blocker in chemically pure form and optionally a pharmaceutically acceptable carrier and optionally adjuvants. The blocker is used in an amount effective against sickle cell anemia. The dosage of the active ingredient depends upon the species, its age, weight, and individual condition, the individual pharmacokinetic data, and the mode of administration. In the case of an individual having a body-weight of about 70 kg the daily dose administered is from approximately 0.001 mg/kg to approximately 10 mg/kg, preferably from approximately 0.05 mg/kg to approximately 1 mg/kg, of a blocker of NMDAR. If memantine hydrochloride is applied in humans, a maximal daily dose of 20mg is administered in adults. To avoid adverse effects a starting dose of 5mg daily is recommended. The dosage should be increased weekly by 5mg a day till the maximal dosage (20mg daily) has been reached. In case of moderate renal insufficiency (Creatinin-Clearance 40-60 ml/min/1.73m²) the maximal dosage should be reduced to 10mg daily.

Pharmaceutical compositions for enteral administration, such as nasal, buccal, rectal or, especially, oral administration, and for parenteral administration, such
as subcutaneous, intravenous, intrahepatic or intramuscular administration, are especially preferred. The pharmaceutical compositions comprise from approximately 1% to approximately 95% active ingredient, preferably from approximately 20% to approximately 90% active ingredient.

For parenteral administration preference is given to the use of solutions of the blockers of NMDAR, and also suspensions or dispersions, especially isotonic aqueous solutions, dispersions or suspensions which, for example, can be made up shortly before use. The pharmaceutical compositions may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, viscosity-increasing agents, salts for regulating osmotic pressure and/or buffers and are prepared in a manner known per se, for example by means of conventional dissolving and lyophilizing processes.

For oral pharmaceutical preparations suitable carriers are especially fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, and also binders, such as starches, cellulose derivatives and/or polyvinylpyrrolidone, and/or, if desired, disintegrators, flow conditioners and lubricants, for example stearic acid or salts thereof and/or polyethylene glycol. Tablet cores can be provided with suitable, optionally enteric, coatings. Dyes or pigments may be added to the tablets or tablet coatings, for example for identification purposes or to indicate different doses of active ingredient. Pharmaceutical compositions for oral administration also include hard capsules consisting of gelatin, and also soft, sealed capsules consisting of gelatin and a plasticizer, such as glycerol or sorbitol. The capsules may contain the active ingredient in the form of granules, or dissolved or suspended in suitable liquid excipients, such as in oils.

Transdermal/intraperitoneal and intravenous applications are also considered, for example using a transdermal patch, which allows administration over an extended period of time, e.g. from one to twenty days.
Intravenous or subcutaneous application are particularly preferred.

Another aspect of the invention relates to the use blockers of NMDAR as described hereinbefore in the treatment of sickle cell anemia, and in the manufacture of medicaments for treating these diseases.

Medicaments according to the invention are manufactured by methods known in the art, especially by conventional mixing, coating, granulating, dissolving or lyophilizing.

The blockers of NMDAR can be administered alone or in combination with one or more other therapeutic agents, possible combination therapy taking the form of fixed combinations of a blocker NMDAR and one or more other therapeutic agents known in the treatment of sickle cell anemia, the administration being staggered or given independently of one another, or being in the form of a fixed combination.

Possible combination partners considered are vitamins B9 and B12 and other medicaments minimizing plasma homocysteine levels. One more group of compounds that could be considered as possible partners are blockers of Gardos channels (such as ICA-17043, see Blood. 2003; 101:2412-2418) and inhibitors of the K+-Cl- cotransporter including magnesium salts.

The invention further relates to a method of screening for a compound effective in the treatment of sickle cell anemia comprising contacting a candidate compound with NMDAR and choosing candidate compounds which selectively reduce the activity of the NMDAR. The invention further relates to compounds selected by these methods of screening.

Blockers of NMDAR activity are identified by contacting the NMDAR with a candidate compound. A control assay with the corresponding NMDAR in the ab-
sence of the candidate compound is run in parallel. A decrease in activity in the
presence of the candidate compound compared to the level in the absence of the
compound indicates that the candidate compound is a NMDAR blocker. NPC-16
Patchliner or Syncropatch 96 (Nanion Technologies GmbH) is optimal for
screening of the candidate NMDAR blockers specifically on human erythrocytes.

Antibodies against the NMDAR can be generated e.g. by immunization of mice.

Concepts and evidence behind the invention

In vitro studies showed that erythrocytes of patients with sickle cell anemia con-
tain more NMDA receptor than that of healthy donors and that these receptors
are predominantly retained in the cell fraction prone or already undergoing sick-
ling (uncontrolled irreversible shrinkage). This cell population looses cell water
and K\(^+\) due to the high permeability of the cell membrane to Ca\(^{2+}\) mediated by
the NMDA receptor. This leads to the conclusion that blocking the NMDA recep-
tor may prevent irreversible shrinkage of erythrocytes of patients with sickle cell
anemia.

Experiments performed

The following experiments were conducted using fresh-isolated human erythro-
cytes of HbSS patients and healthy subjects.

Experiment 1

Localization of the NMDA receptors in erythrocytes of patients and healthy sub-
jects was studied using immunoblotting (Fig 1) and in cells treated with a selec-
tive irreversible blocker of the NMDA receptor 3H-MK-801. The number of the
MK-801 binding sites per erythrocyte was assessed in sub-populations of cells
with different densities (potential age groups). To do so the erythrocyte suspen-
sions in the medium containing (mM) 145 NaCl, 4KCl, 1CaCl\(_2\), 0.15 MgCl\(_2\), 10
sucrose, 10 glucose, 10 Tris-HCl (pH 7.4) were incubated at room temperature
for 30 min in the presence of 3H-MK-801. Thereafter the cells were washed from
external radioactivity and separated on the Percoll density gradient (see Lutz et al., Biochim Biophys Acta 1992 Mar 5:1 116(1):1 - 10). Cell sub-populations of different densities were then isolated, washed and lysed with distilled water. Membranes were then collected by centrifugation, dissolved in the scintillation fluid (Quicksafe A, Zinsser Analytic) and the amount of 3H-MK-801 assessed by beta counter and normalized to the amount of cells. Receptors were equally distributed between reticulocytes and young cells (8±1 receptors per cell), mature cells (8±3) dense senescent cell population (7±2). In patients with HbSS the number of receptor copies per cell was higher in all cell populations (50±2, 17±5 and 19±10 receptors per cell in young, mature and senescent sub-populations respectively). When blocker-free the young cells were the first to undergo sickling and shrinkage as the receptor is predominantly present in the dense population (cells prone to sickling).

**Experiment 2**

Fluxes via the nonselective cation channel of the NMDA receptor were assessed using radioactive tracer kinetics. 86Rb was used as a radioactive tracer for K+ and 45Ca as a tracer for Ca²⁺. Fluxes through the red cell membrane were measures in the medium containing (mM) 145 Na-methane sulfate, 4 K-glucuronate, 1 Ca-gluconate, 10 sucrose, 10 glucose and 10 HEPES-Ths (pH 7.4) in the presence of 100 µM L-arginine and 100 µM ouabain. Details of the flux measurement may be found elsewhere (e.g. Bogdanova et al., J Membr Biol. 2003;1 95(1):33-42). Erythrocytes of the HbSS patients showed higher passive K⁺ and Ca²⁺ fluxes that may be blocked by MK-801 (50 µM) or the reversible inhibitor of the NMDA receptor used in treatment of Alzheimer disease, memantine (50 µM). Fluxes of both cations are further stimulated by NMDA (100 µM) or prostaglandine E2 (2 µM). Both NMDA- and PGE2-sensitive increase in fluxes could be blocked by MK-801 or memantine. Fluxes through the NMDA receptors were significantly higher in patients with sickle cell anemia during the flue incidents which corresponded to the anemic crisis and hospitalization.
Experiment 3
High levels of the NMDA receptors and sensitization of HbSS patients' erythrocytes to NMDA treatment was shown. There was no direct correlation of the abundance of receptors in red cells and the amount of reticulocytes (routine blood status analysis), but rather with specific hematological disorders such as sickle cell anemia. Functional activity of the receptors was assessed by measuring K+(86Rb) influx through the receptor channels and 3H-MK-801 finding studies. Routine screening of control individuals for the receptor expression in erythrocytes revealed that one of them with abnormally high number of receptor copies had beta-thalassemia minor.

Experiment 4
Abnormally high sensitivity of the HbSS erythrocytes to NMDA treatment can be followed microscopically as changes in cell morphology. Shown in Fig 3 are the cells of healthy donors and HbSS patients exposed to 1 mM NMDA with and without pre-treatment with 50 µM of MK-801/memantine.

Clinical Study. Treatment of patients with sickle cell anemia with NMDAR blocker (suggested study).
A prospective phase II clinical feasibility study in human sickle cell patients with a NMDAR blocker can be performed as follows: It starts with an oral treatment with memantine hydrochloride. The maximal daily dose is analogous to the clinical experiences in Alzheimer disease, i.e. 20mg with a starting dose of 5mg daily and if tolerability is good a weekly increase of 5mg a day till the maximal tolerable dosage has been reached. In case of moderate renal insufficiency (Creatinin-Clearance 40-60 ml/min/1.73m2) the maximal dosage is reduced to 10mg daily. The treatment with memantine hydrochloride will be continued for one year and during this time all adverse events due to sickle cell anemia and possible side effects of the treatment are monitored. These data are compared with the history of the patient under best supportive care during the year before inclusion in the study. Endpoints of the study are severity and frequency of ad-
verse events due to sickle cell anemia and tolerability of the treatment with memantine hydrochloride.
Claims

1. A N-methyl D-aspartate receptor (NMDAR) blocker for the treatment of sickle cell anemia.

2. Use of a N-methyl D-aspartate receptor (NMDAR) blocker in the manufacture of a medicament for the treatment of sickle cell anemia.

3. A method for screening for a compound effective in the treatment of sickle cell anemia, comprising contacting a candidate compound with the NMDAR and selecting said candidate compound as effective if it is found to selectively reduce activity of the NMDAR.

4. A compound for the treatment of sickle cell anemia, selected by the method of claim 3.
Fig 1
## INTERNATIONAL SEARCH REPORT

### A. CLASSIFICATION OF SUBJECT MATTER

<table>
<thead>
<tr>
<th>INV.</th>
<th>ADD.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A61K31/00</td>
<td>A61K31/13</td>
</tr>
</tbody>
</table>

According to International Patent Classification (IPC) or to both national classification and IPC.

### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

### C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document with indication, where appropriate of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
</table>

Further documents are listed in the continuation of Box C. See patent family annex.

Special categories of cited documents

'A' document defining the general state of the art which is not considered to be of particular relevance

'E' earlier document but published on or after the international filing date

'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

'O' document referring to an oral disclosure, use exhibition or other means

'P' document published prior to the international filing date but later than the priority date claimed

'Y' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

'X' document of particular relevance the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

'Y' document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

'Z' document of the same patent family

Date of the actual completion of the international search

30 June 2010

Date of mailing of the international search report

14/07/2010

Name and mailing address of the ISA/

European Patent Office, P B 5818 Patentlaan 2 NL- 2280 HV Rijswijk

Tel (+31-70) 340-2040

Fax (+31-70) 340-3016

Authorized officer

Loher, Florian
<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
</table>